PMID- 38001666
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231127
IS  - 2072-6694 (Print)
IS  - 2072-6694 (Electronic)
IS  - 2072-6694 (Linking)
VI  - 15
IP  - 22
DP  - 2023 Nov 14
TI  - Therapeutic Efficacy and Safety of Lenvatinib after Atezolizumab Plus Bevacizumab 
      for Unresectable Hepatocellular Carcinoma.
LID - 10.3390/cancers15225406 [doi]
LID - 5406
AB  - A total of 137 HCC patients treated with atezolizumab plus bevacizumab from 
      October 2020 to September 2022 were enrolled. The median overall survival (OS) 
      and progression-free survival (PFS) from the beginning of atezolizumab plus 
      bevacizumab were 21.1 months (range, 18.8 months-not reached) and 10.5 months 
      (range, 8.2-12.1 months), respectively. Fifty patients were diagnosed with 
      progressive disease after atezolizumab plus bevacizumab. Of this group, 24 
      patients were administered lenvatinib, and the median OS and PFS from the 
      beginning of lenvatinib were 15.3 months (range, 10.5 months-not reached) and 4.0 
      months (range, 2.5-6.4 months), respectively. The objective response rates based 
      on the response evaluation criteria in solid tumors (RECISTs) criteria version 
      1.1 and modified RECISTs were 33.3% and 54.2%, respectively. There was no 
      significant difference in the median serum alpha-fetoprotein level between before 
      and after lenvatinib. In the multivariate analysis, Child-Pugh class A (hazard 
      ratio 0.02, 95% confidence interval (CI) 0.02-0.76, p = 0.02) and intrahepatic 
      tumor occupancy rate < 50% (hazard ratio < 0.01, 95% CI 0.003-0.35, p < 0.01) 
      were the significant factors for OS. There were some frequent adverse events 
      (AEs) in patients treated with lenvatinib such as hypertension, fatigue, 
      anorexia, proteinuria, and so on, but none directly caused death. In conclusion, 
      lenvatinib after atezolizumab plus bevacizumab for unresectable HCC should be 
      considered an effective treatment option.
FAU - Yano, Shigeki
AU  - Yano S
AD  - Department of Gastroenterology, Graduate School of Biomedical and Health 
      Sciences, Hiroshima University, Hiroshima 734-8551, Japan.
FAU - Kawaoka, Tomokazu
AU  - Kawaoka T
AD  - Department of Gastroenterology, Graduate School of Biomedical and Health 
      Sciences, Hiroshima University, Hiroshima 734-8551, Japan.
FAU - Yamasaki, Shintaro
AU  - Yamasaki S
AD  - Department of Gastroenterology, Graduate School of Biomedical and Health 
      Sciences, Hiroshima University, Hiroshima 734-8551, Japan.
FAU - Johira, Yusuke
AU  - Johira Y
AD  - Department of Gastroenterology, Graduate School of Biomedical and Health 
      Sciences, Hiroshima University, Hiroshima 734-8551, Japan.
FAU - Kosaka, Masanari
AU  - Kosaka M
AD  - Department of Gastroenterology, Graduate School of Biomedical and Health 
      Sciences, Hiroshima University, Hiroshima 734-8551, Japan.
FAU - Shirane, Yuki
AU  - Shirane Y
AD  - Department of Gastroenterology, Graduate School of Biomedical and Health 
      Sciences, Hiroshima University, Hiroshima 734-8551, Japan.
FAU - Miura, Ryoichi
AU  - Miura R
AD  - Department of Gastroenterology, Graduate School of Biomedical and Health 
      Sciences, Hiroshima University, Hiroshima 734-8551, Japan.
FAU - Amioka, Kei
AU  - Amioka K
AUID- ORCID: 0000-0002-6658-5203
AD  - Department of Gastroenterology, Graduate School of Biomedical and Health 
      Sciences, Hiroshima University, Hiroshima 734-8551, Japan.
FAU - Naruto, Kensuke
AU  - Naruto K
AUID- ORCID: 0000-0003-1128-0960
AD  - Department of Gastroenterology, Graduate School of Biomedical and Health 
      Sciences, Hiroshima University, Hiroshima 734-8551, Japan.
FAU - Yamaoka, Kenji
AU  - Yamaoka K
AD  - Department of Gastroenterology, Graduate School of Biomedical and Health 
      Sciences, Hiroshima University, Hiroshima 734-8551, Japan.
FAU - Fujii, Yasutoshi
AU  - Fujii Y
AD  - Department of Gastroenterology, Graduate School of Biomedical and Health 
      Sciences, Hiroshima University, Hiroshima 734-8551, Japan.
FAU - Uchikawa, Shinsuke
AU  - Uchikawa S
AUID- ORCID: 0000-0002-1538-4946
AD  - Department of Gastroenterology, Graduate School of Biomedical and Health 
      Sciences, Hiroshima University, Hiroshima 734-8551, Japan.
FAU - Fujino, Hatsue
AU  - Fujino H
AD  - Department of Gastroenterology, Graduate School of Biomedical and Health 
      Sciences, Hiroshima University, Hiroshima 734-8551, Japan.
FAU - Ono, Atsushi
AU  - Ono A
AUID- ORCID: 0000-0002-2482-945X
AD  - Department of Gastroenterology, Graduate School of Biomedical and Health 
      Sciences, Hiroshima University, Hiroshima 734-8551, Japan.
FAU - Nakahara, Takashi
AU  - Nakahara T
AD  - Department of Gastroenterology, Graduate School of Biomedical and Health 
      Sciences, Hiroshima University, Hiroshima 734-8551, Japan.
FAU - Murakami, Eisuke
AU  - Murakami E
AD  - Department of Gastroenterology, Graduate School of Biomedical and Health 
      Sciences, Hiroshima University, Hiroshima 734-8551, Japan.
FAU - Miki, Daiki
AU  - Miki D
AD  - Department of Gastroenterology, Graduate School of Biomedical and Health 
      Sciences, Hiroshima University, Hiroshima 734-8551, Japan.
FAU - Tsuge, Masataka
AU  - Tsuge M
AUID- ORCID: 0000-0001-7591-8287
AD  - Department of Gastroenterology, Graduate School of Biomedical and Health 
      Sciences, Hiroshima University, Hiroshima 734-8551, Japan.
FAU - Teraoka, Yuji
AU  - Teraoka Y
AD  - Department of Gastroenterology, National Hospital Organization Kure Medical 
      Center and Chugoku Cancer Center, Hiroshima 737-0023, Japan.
FAU - Kouno, Hirotaka
AU  - Kouno H
AD  - Department of Gastroenterology, National Hospital Organization Kure Medical 
      Center and Chugoku Cancer Center, Hiroshima 737-0023, Japan.
FAU - Takaki, Shintaro
AU  - Takaki S
AD  - Department of Gastroenterology, Hiroshima Red Cross Hospital and Atomic-Bomb 
      Survivors Hospital, Hiroshima 730-8619, Japan.
FAU - Mori, Nami
AU  - Mori N
AD  - Department of Gastroenterology, Hiroshima Red Cross Hospital and Atomic-Bomb 
      Survivors Hospital, Hiroshima 730-8619, Japan.
FAU - Tsuji, Keiji
AU  - Tsuji K
AD  - Department of Gastroenterology, Hiroshima Red Cross Hospital and Atomic-Bomb 
      Survivors Hospital, Hiroshima 730-8619, Japan.
FAU - Oka, Shiro
AU  - Oka S
AD  - Department of Gastroenterology, Graduate School of Biomedical and Health 
      Sciences, Hiroshima University, Hiroshima 734-8551, Japan.
LA  - eng
PT  - Journal Article
DEP - 20231114
PL  - Switzerland
TA  - Cancers (Basel)
JT  - Cancers
JID - 101526829
PMC - PMC10670624
OTO - NOTNLM
OT  - first-line therapy
OT  - immune checkpoint inhibitor
OT  - molecular-targeted agent
OT  - second-line therapy
COIS- The authors declare no conflict of interest.
EDAT- 2023/11/25 12:43
MHDA- 2023/11/25 12:44
PMCR- 2023/11/14
CRDT- 2023/11/25 01:05
PHST- 2023/09/30 00:00 [received]
PHST- 2023/11/11 00:00 [revised]
PHST- 2023/11/13 00:00 [accepted]
PHST- 2023/11/25 12:44 [medline]
PHST- 2023/11/25 12:43 [pubmed]
PHST- 2023/11/25 01:05 [entrez]
PHST- 2023/11/14 00:00 [pmc-release]
AID - cancers15225406 [pii]
AID - cancers-15-05406 [pii]
AID - 10.3390/cancers15225406 [doi]
PST - epublish
SO  - Cancers (Basel). 2023 Nov 14;15(22):5406. doi: 10.3390/cancers15225406.